Literature DB >> 17127075

Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats.

Fuhai Li1, Wei Xia, Aiwu Li, Cuifen Zhao, Ruopeng Sun.   

Abstract

Accumulating evidences have demonstrated that RhoA/Rho-kinase pathway plays a pivotal role in various cellular functions. The aim of this study was to explore whether RhoA/Rho-kinase pathway is involved in the pathogenesis of high flow induced pulmonary hypertension and whether long-term inhibition of RhoA/Rho-kinase pathway with fasudil could attenuate high flow induced pulmonary artery remodeling in rats. Wistar rats in the shunt groups and treated groups were underwent left common carotid artery-external jugular vein shunt operation, rats in control groups were sham-operated animals. Rats in treated groups received fasudil treatment, the others received same dose of saline. At week 4, 8 of the study, rats were underwent haemodynamics measurements, pulmonary artery morphologic assessments, detection of pulmonary artery smooth muscle cells (SMCs) proliferation and apoptosis. RhoA and Rho-kinase activity in pulmonary arteries were also analyzed. Compared with the control groups, exposure to high blood flow induced a significant elevation of right ventricle systolic pressure at week 8, significant increase of the mean percentage of media wall thickness (%MT) in moderate size pulmonary arteries both at weeks 4 and 8, marked elevation of right ventricle (RV) to left ventricle plus septum (LV+SP) weight ratio at week 8, significant increase of PCNA-positive SMCs percentage at week 4 and significant decrease of TUNEL-positive SMCs percentage both at weeks 4 and 8. High pulmonary blood flow also induced 3.19+/-0.28-fold increase of RhoA and 3.63+/-0.52-fold increase of Rho-kinase over the control group at week 4, 1.57+/-0.35-fold increase of RhoA and 2.36+/-0.39-fold increase of Rho-kinase over the control group at week 8. Compared with the shunt groups, fasudil treatment significantly suppressed Rho-kinase activity at both weeks 4 and 8, improved pulmonary hypertension at week 8, attenuated right ventricular hypertrophy at week 8, and enhanced pulmonary vascular remodeling both at weeks 4 and 8, which were associated with suppressed pulmonary artery smooth muscle cells proliferation at week 4 and apoptosis both at weeks 4 and 8. These results indicated that RhoA/Rho-kinase mediated pathway participated in the process of high flow induced pulmonary artery remodeling; inhibition of Rho kinase with fasudil could attenuate pulmonary artery remodeling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127075     DOI: 10.1016/j.phrs.2006.10.009

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  18 in total

1.  Role of the cytoskeleton in flow (shear stress)-induced dilation and remodeling in resistance arteries.

Authors:  Laurent Loufrani; Daniel Henrion
Journal:  Med Biol Eng Comput       Date:  2008-05       Impact factor: 2.602

Review 2.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 3.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 4.  Novel strategy for treatment of pulmonary arterial hypertension: enhancement of apoptosis.

Authors:  Jing-bin Huang; Ying-long Liu; Pei-wu Sun; Xiao-dong Lv; Kong Bo; Xiang-ming Fan
Journal:  Lung       Date:  2010-03-06       Impact factor: 2.584

Review 5.  Rho kinase as a target for cerebral vascular disorders.

Authors:  Lisa M Bond; James R Sellers; Lisa McKerracher
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

6.  Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension.

Authors:  Rong Jiang; Zi-Sheng Ai; Xin Jiang; Ping Yuan; Dong Liu; Qin-Hua Zhao; Jing He; Lan Wang; Mardi Gomberg-Maitland; Zhi-Cheng Jing
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

Review 7.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

8.  Fasudil inhibits the myogenic response in the fetal pulmonary circulation.

Authors:  Pierre Tourneux; Marc Chester; Theresa Grover; Steven H Abman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-01       Impact factor: 4.733

9.  Interventional Transcatheter Closure Ameliorates the Leukocyte Rho Kinase Activities among Patients with Patent Ductus Arteriosus.

Authors:  Min-Ling Hsieh; Ping-Yen Liu; Jing-Ming Wu; James K Liao; Jieh-Neng Wang
Journal:  Acta Cardiol Sin       Date:  2015-11       Impact factor: 2.672

Review 10.  RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.

Authors:  Scott A Barman; Shu Zhu; Richard E White
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.